Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases

NEXT STORY
Philips and Regional Medical Center announce USD 16 million, long-term strategic partnership to innovate patient care for residents of rural South Carolina
PREV STORY
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RAMSAY GENERALE DE SANTE to complete the public offer to the shareholders of Capio

PRESS RELEASE THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED ...

author_avatar
NASDAQ Market News

Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinical Trials

ORLANDO, Fla., May 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) would ...

author_avatar
NASDAQ Market News

Evelo Biosciences Announces Pricing of Public Offering of Common Stock

author_avatar
NASDAQ Market News